|
CELG's Revenue Growth by Quarter and Year
Celgene's Revenue results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| CELG Revenue (in millions $) |
FY 2019 |
FY 2018 |
FY 2017 |
FY 2016 |
| IV Quarter |
December |
-
|
4,037.00
|
3,483.00
|
2,980.50
|
| III Quarter |
September |
4,520.00
|
3,892.00
|
3,287.00
|
2,982.80
|
| II Quarter |
June |
4,400.00
|
3,814.00
|
3,268.00
|
2,754.30
|
| I Quarter |
March |
4,025.00
|
3,538.00
|
2,960.00
|
2,511.60
|
| FY |
|
12,945.00
|
15,281.00
|
12,998.00
|
11,229.20
|
| CELG Revenue third quarter 2019 Y/Y Growth Comment |
Celgene Corp reported Revenue increase of 16.14% year on year in the third quarter, to $ 4,520.00 millions, this is lower than Celgene Corp's recent average Revenue improvement of 30.14%.
Looking into third quarter results within Major Pharmaceutical Preparations industry 81 other companies have achieved higher Revenue growth. While Celgene Corp' s Revenue growth of 16.14% ranks overall at the positon no. 1003 in the third quarter.
|
| CELG Revenue ( Y/Y Growth %) |
2019
|
2018 |
2017 |
2016 |
| IV Quarter |
December |
- |
15.91 % |
16.86 % |
16.28 % |
| III Quarter |
September |
16.14 % |
18.41 % |
10.2 % |
27.79 % |
| II Quarter |
June |
15.36 % |
16.71 % |
18.65 % |
20.92 % |
| I Quarter |
March |
13.76 % |
19.53 % |
17.85 % |
20.7 % |
| FY |
|
- |
17.56 % |
15.75 % |
21.32 % |
CELG Revenue (Quarter on Quarter Growth %) |
2019
|
2018 |
2017 |
2016 |
| IV Quarter |
December |
- |
3.73 % |
5.96 % |
-0.08 % |
| III Quarter |
September |
2.73 % |
2.05 % |
0.58 % |
8.3 % |
| II Quarter |
June |
9.32 % |
7.8 % |
10.41 % |
9.66 % |
| I Quarter |
March |
-0.3 % |
1.58 % |
-0.69 % |
-2.02 % |
| FY (Year on Year) |
|
- |
17.56 % |
15.75 % |
21.32 % |
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 89.06 % |
30.14 % |
10.01 % |
| (Sep. 30, 2006) |
|
(June 30. 2009) |
|
|
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 89.06 % |
30.14 % |
10.01 % |
| (Sep. 30, 2006) |
|
(June 30. 2009) |
|
| Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019 |
Celgene's Q/Q Revenue Growth
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 29.63 % |
6.81 % |
-11.12 % |
| (June 30. 2005) |
|
(Sep. 30, 2005) |
| CELG's III. Quarter Q/Q Revenue Comment |
Celgene Corp achieved in the III. Quarter 2019 below company average Revenue growth of 2.73% quarter on quarter, to $ 4,520.00 millions.
Even if the III. Quarter 2019 results were lower than the ordinary of 6.81 %, this has been still encouraging news, as the III. Quarter expension, transcends the 2.05% Revenue rise in the same quarter a year ago
Within Major Pharmaceutical Preparations industry 91 other companies have achieved higher Revenue quarter on quarter growth. While Celgene's Revenue growth quarter on quarter, overall rank is 1700. |
|
|
|
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 29.63 % |
6.81 % |
-11.12 % |
| (June 30. 2005) |
|
(Sep. 30, 2005) |
| CELG's III. Quarter Q/Q Revenue Comment |
Celgene Corp achieved in the III. Quarter 2019 below company average Revenue growth of 2.73% quarter on quarter, to $ 4,520.00 millions.
Although the III. Quarter 2019 performance was below the ordinary , that has been yet promising news, as the III. Quarter improvement, outshines the 2.05% rise in the same quarter a year ago
Within Major Pharmaceutical Preparations industry 91 other companies have achieved higher Revenue quarter on quarter growth. While Celgene's Revenue growth quarter on quarter, overall rank is 1700. |
|
Celgene's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending
(Sep 30 2019) |
12 Months Ending
(Jun 30 2019) |
12 Months Ending
(Mar 31 2019) |
12 Months Ending
(Dec 31 2018) |
12 Months Ending
(Sep 30 2018) |
| Cumulative Revenue 12 Months Ending |
$ 16,982.00 |
$ 16,354.00 |
$ 15,768.00 |
$ -8,584.00 |
$ 14,727.00 |
| Y / Y Revenue Growth (TTM) |
15.31 % |
15.81 % |
16.15 % |
- |
17.86 % |
| Year on Year Revenue Growth Overall
Ranking |
# 1004 |
# 1019 |
# 1013 |
# 0 |
# 1022 |
| Seqeuential Revenue Change (TTM) |
3.84 % |
3.72 % |
3.19 % |
- |
4.28 % |
| Seq. Revenue Growth (TTM) Overall
Ranking |
# 1007 |
# 1024 |
# 1005 |
# 1007 |
# 1159 |
| Cumulative Revenue growth
Comment |
With the quarterly Revenue reported in the Sep 30 2019 period, Celgene's cumulative twelve months Revenue were $ 16,982 millions, company would post below average annual Revenue growth of 4.28% year on year, if the fiscal year would end at Sep 30 2019.
A slow-down in the Celgene's Revenue growth from the 4400% growth in Jun 30 2019.
In the Healthcare sector 200 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1004, from total ranking in previous quarter at 1019. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
17.53 % |
5.91 % |
-24.75 % |
|
|
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
80.99 % |
31.73 % |
3.88 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 77 |
| Sector |
# 215 |
| S&P 500 |
# 1007 |
|
| Cumulative Revenue growth
Comment |
With the quarterly Revenue reported in the Sep 30 2019 period, Celgene's cumulative twelve months Revenue were $ 16,982 millions, company would post below average annual Revenue growth of 3.88% year on year, if the fiscal year would end at Sep 30 2019.
A slow-down in the Celgene's Revenue growth from the 4400% growth in Jun 30 2019.
In the Healthcare sector 200 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1004, from total ranking in previous quarter at 1019. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
17.53 % |
5.91 % |
-24.75 % |
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
80.99 % |
31.73 % |
3.88 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 77 |
| Sector |
# 215 |
| S&P 500 |
# 1007 |
|
27.37%